Angiogenesis Gene Therapy Phase I Assessment of Direct Intramyocardial Administration of an Adenovirus Vector Expressing VEGF121 cDNA to Individuals With Clinically Significant Severe Coronary Artery Disease

摘要: Background—Therapeutic angiogenesis, a new experimental strategy for the treatment of vascular insufficiency, uses administration mediators known to induce development in embryogenesis neovascularization ischemic adult tissues. This report summarizes phase I clinical experience with gene-therapy that used an E1−E3− adenovirus (Ad) gene-transfer vector expressing human endothelial growth factor (VEGF) 121 cDNA (AdGVVEGF121.10) therapeutic angiogenesis myocardium individuals clinically significant coronary artery disease. Methods and Results—AdGVVEGF121.10 was administered 21 by direct myocardial injection into area reversible ischemia either as adjunct conventional bypass grafting (group A, n=15) or sole therapy via minithoracotomy B, n=6). There no evidence systemic cardiac-related adverse events related administration. In both groups, angiography ...